Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

被引：0

作者：

Samuel Murray

Vasilios Karavasilis

Mattheos Bobos

Evangelia Razis

Savvas Papadopoulos

Christos Christodoulou

Paris Kosmidis

George Fountzilas

机构：

[1] BioMarker Solutions Ltd,Department of Molecular Oncology

[2] GeneKOR,Department of Medical Oncology

[3] “Papageorgiou” Hospital,Department of Pathology

[4] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology

[5] Aristotle University of Thessaloniki School of Medicine,Department of Pathology

[6] “Hygeia” Hospital,Second Department of Medical Oncology

[7] “Hygeia” Hospital,Second Department of Medical Oncology

[8] “Metropolitan” Hospital,undefined

[9] “Hygeia” Hospital,undefined

来源：

Journal of Experimental & Clinical Cancer Research | / 31卷

关键词：

Predictive; Somatic mutation; EGFR; Gefitinib; Erlotinib; Response;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
Passaro, Antonio
Cortesi, Enrico
de Marinis, Filippo
EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (10) : 1587 - 1597
[22] Potential role of multi-targeted inhibitors in non-small-cell lung tyrosine kinase cancer
Scagliotti, G. V.
ANNALS OF ONCOLOGY, 2007, 18 : 32 - 41
[23] Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
Subramanian, Janakiraman
Morgensztern, Daniel
Govindan, Ramaswamy
CLINICAL LUNG CANCER, 2010, 11 (05) : 311 - 319
[24] Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors
Pilotto, Sara
Bria, Emilio
LUNG CANCER MANAGEMENT, 2013, 2 (02) : 89 - 92
[25] Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.
Aydiner, Adnan
Dogan, Izzet
Khanmammadov, Nijat
Saip, Pinar
Vatansever, Sezai
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[26] Protein kinase inhibitors to treat non-small-cell lung cancer
Minuti, Gabriele
D'Incecco, Armida
Landi, Lorenza
Cappuzzo, Federico
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (09) : 1203 - 1213
[27] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
Gazdar, A. F.
ONCOGENE, 2009, 28 : S24 - S31
[28] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
A F Gazdar
Oncogene, 2009, 28 : S24 - S31
[29] Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?
Morin-Ben Abdallah, S.
Wong, A.
CURRENT ONCOLOGY, 2018, 25 : S103 - S114
[30] Ceritinib: A New Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer
Cooper, Maryann R.
Chim, Helen
Chan, Hoyi
Durand, Cheryl
ANNALS OF PHARMACOTHERAPY, 2015, 49 (01) : 107 - 112

← 1 2 3 4 5 →